Skip to content

STEMLINE THERAPEUTICS INC: 10-Q filed 2018-11-08

What STEMLINE THERAPEUTICS INC reported in its quarterly report filed 2018-11-08 (fiscal Q3 2018): 31 published measures, 84 facts as tagged in accession 0001104659-18-066974.

This filing

Form
10-Q (quarterly report)
Filed
2018-11-08
Fiscal period
fiscal Q3 2018
Accession
0001104659-18-066974 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All STEMLINE THERAPEUTICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-09-3080,964,600USD
At 2017-12-3167,006,168USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-09-3017,426,434USD
At 2017-12-3119,935,739USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-09-3063,538,166USD
At 2017-12-3147,070,429USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-09-3011,677,741USD
At 2017-12-314,795,098USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-07-01 to 2018-09-30-21,043,996USD92
2018-01-01 to 2018-09-30-58,389,451USD273
2003-08-01 to 2018-09-30-274,100,000USD5540
2017-07-01 to 2017-09-30-16,056,147USD92
2017-01-01 to 2017-09-30-46,079,093USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-09-30-53,740,588USD273
2017-01-01 to 2017-09-30-35,894,434USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2018-01-01 to 2018-09-30500,000USD273
2017-07-01 to 2017-09-30299,397USD92
2017-01-01 to 2017-09-30898,199USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-09-3066,079,942USD273
2017-01-01 to 2017-09-3048,371,064USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-09-30-5,456,711USD273
2017-01-01 to 2017-09-30-12,527,338USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-09-30-262,453,150USD
At 2017-12-31-204,275,690USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-09-30221,820USD
At 2017-12-31136,672USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-09-308,682,492USD273
2017-01-01 to 2017-09-306,178,079USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-07-01 to 2018-09-30-21,405,361USD92
2018-01-01 to 2018-09-30-59,358,698USD273
2017-07-01 to 2017-09-30-16,270,704USD92
2017-01-01 to 2017-09-30-46,619,661USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-09-3080,530,475USD
At 2017-12-3152,188,777USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2018-07-01 to 2018-09-30350USD92
2018-01-01 to 2018-09-30473USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-09-3017,335,260USD
At 2017-12-3119,838,913USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-07-01 to 2018-09-3021,405,361USD92
2018-01-01 to 2018-09-3059,858,698USD273
2017-07-01 to 2017-09-3016,570,101USD92
2017-01-01 to 2017-09-3047,517,860USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-07-01 to 2018-09-3011,758,025USD92
2018-01-01 to 2018-09-3035,650,147USD273
2017-07-01 to 2017-09-3012,417,652USD92
2017-01-01 to 2017-09-3033,517,006USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-09-3031,671,552shares
At 2017-12-3125,313,595shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2018-09-3011,677,741USD
At 2017-12-314,795,098USD
At 2017-09-3010,265,356USD
At 2016-12-3110,316,064USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-09-30-96,546USD
At 2018-06-30-122,973USD
At 2017-12-31-145,958USD
At 2017-09-30-87,683USD
At 2017-06-30-120,897USD
At 2016-12-31-99,802USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2018-09-30739,156USD
At 2017-12-31615,369USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-09-30517,336USD
At 2017-12-31478,697USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-09-30212,305USD
At 2017-12-31212,305USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-09-3091,174USD
At 2017-12-3196,826USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-09-301,996,235USD
At 2017-12-31469,067USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2018-01-01 to 2018-09-30-58,389,451USD273
2017-01-01 to 2017-09-30-46,079,093USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-07-01 to 2018-09-30-21,017,569USD92
2018-01-01 to 2018-09-30-58,340,039USD273
2017-07-01 to 2017-09-30-16,022,933USD92
2017-01-01 to 2017-09-30-46,066,974USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-07-01 to 2018-09-309,647,336USD92
2018-01-01 to 2018-09-3024,208,551USD273
2017-07-01 to 2017-09-304,152,449USD92
2017-01-01 to 2017-09-3014,000,854USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-07-01 to 2018-09-3014,575USD92
2018-01-01 to 2018-09-3038,639USD273
2017-07-01 to 2017-09-30952USD92
2017-01-01 to 2017-09-302,856USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-01-01 to 2018-09-3064,003,764USD273
2017-01-01 to 2017-09-3048,242,214USD273

Inspect the source

Entity
STEMLINE THERAPEUTICS INC / CIK 0001264587
Captured
SEC response SHA-256
4bc563f579ac3611fca3a4b0f91dded31bf19c0e78ed6a10086fa540610de496

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001264587.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))